# LTSE-2578 PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/ltse-2578

> LTSE-2578, sponsored by Structure Therapeutics Inc. (GPCR): 2 recorded catalysts.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | LTSE-2578 |
| Codes | LTSE-2578 |
| Sponsor | Structure Therapeutics Inc. (GPCR) https://sec-api.dev/companies/gpcr/catalysts |
| Indications | [idiopathic pulmonary fibrosis](https://sec-api.dev/indications/idiopathic-pulmonary-fibrosis) |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### Jun 2024: trial start

- Status: completed. Date confidence: month. Stage: 1. Indication: idiopathic pulmonary fibrosis.
- First seen 2024-11-13, last confirmed 2025-05-08.
- SEC Form 10-Q (accession 0001558370-25-006989): "In June 2024, we initiated a Phase 1 clinical study of LTSE-2578, our oral small molecule antagonist that targets the lysophosphatidic acid 1 receptor ("LPA1R") for the treatment of idiopathic pulmonary fibrosis ("IPF")." https://www.sec.gov/Archives/edgar/data/1888886/000155837025006989/gpcr-20250331x10q.htm
- SEC Form 10-Q (accession 0001558370-25-006989): "In June 2024, we initiated a Phase 1 clinical trial of LTSE-2578." https://www.sec.gov/Archives/edgar/data/1888886/000155837025006989/gpcr-20250331x10q.htm
- SEC Form 10-K (accession 0001558370-25-001826): "In June 2024, we initiated our first-in-human Phase 1 study of LTSE-2578." https://www.sec.gov/Archives/edgar/data/1888886/000155837025001826/gpcr-20241231x10k.htm
- SEC Form 10-K (accession 0001558370-25-001826): "In June 2024, we initiated a Phase 1 clinical study of LTSE-2578." https://www.sec.gov/Archives/edgar/data/1888886/000155837025001826/gpcr-20241231x10k.htm
- SEC Form 10-K (accession 0001558370-25-001826): "In June 2024, we initiated a Phase 1 clinical trial of LTSE-2578." https://www.sec.gov/Archives/edgar/data/1888886/000155837025001826/gpcr-20241231x10k.htm
- SEC Form 10-Q (accession 0001558370-24-015531): "In June 2024, we initiated a Phase 1 clinical study of LTSE-2578, our oral small molecule antagonist that targets the lysophosphatidic acid 1 receptor ("LPA1R") for the treatment of idiopathic pulmonary fibrosis ("IPF")." https://www.sec.gov/Archives/edgar/data/1888886/000155837024015531/gpcr-20240930x10q.htm
- SEC Form 10-Q (accession 0001558370-24-015531): "In June 2024, we initiated a Phase 1 clinical trial of LTSE-2578." https://www.sec.gov/Archives/edgar/data/1888886/000155837024015531/gpcr-20240930x10q.htm

### 2025: interim data readout

- Status: scheduled. Date confidence: year.
- First seen 2025-02-27, last confirmed 2025-05-08.
- SEC Form 10-Q (accession 0001558370-25-006989): "The randomized, double-blind, placebo-controlled first-in-human clinical study is designed to investigate the safety, tolerability and pharmacokinetics of single and multiple ascending doses of LTSE-2578 in approximately 64 healthy participants and we expect to report initial data in 2025." https://www.sec.gov/Archives/edgar/data/1888886/000155837025006989/gpcr-20250331x10q.htm
- SEC Form 10-Q (accession 0001558370-25-006989): "The randomized, double-blind, placebo-controlled first-in-human clinical trial is designed to investigate the safety, tolerability and pharmacokinetics of single and multiple ascending doses of LTSE-2578 in approximately 64 healthy participants and expect to report initial data in 2025." https://www.sec.gov/Archives/edgar/data/1888886/000155837025006989/gpcr-20250331x10q.htm
- SEC Form 10-K (accession 0001558370-25-001826): "This randomized, double-blind, placebo-controlled first-in-human clinical study is designed to investigate the safety, tolerability and PK of single and multiple ascending doses of LTSE-2578 in approximately 64 healthy participants and expect to report initial data in 2025." https://www.sec.gov/Archives/edgar/data/1888886/000155837025001826/gpcr-20241231x10k.htm
- SEC Form 10-K (accession 0001558370-25-001826): "The randomized, double-blind, placebo-controlled first-in-human clinical trial is designed to investigate the safety, tolerability and pharmacokinetics of single and multiple ascending doses of LTSE-2578 in approximately 64 healthy participants and expect to report initial data in 2025." https://www.sec.gov/Archives/edgar/data/1888886/000155837025001826/gpcr-20241231x10k.htm

## Same indication

- [NIKTIMVO (axatilimab)](https://sec-api.dev/pdufa/axatilimab) (INCY)
- [LTI-03](https://sec-api.dev/pdufa/lti-03) (RNTX)
- [Ofev® (nintedanib)](https://sec-api.dev/pdufa/nintedanib) (AVLN)
- [TTI-101](https://sec-api.dev/pdufa/tti-101) (TVRD)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/ltse-2578.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "LTSE-2578 PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/ltse-2578

```bibtex
@misc{secapidev_pdufa_ltse_2578_20261116,
  title        = {LTSE-2578 PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/ltse-2578}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_ltse_2578_20261116","title":"LTSE-2578 PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/ltse-2578","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
